Exercise of Options & Total Voting Rights
Poolbeg Pharma PLC has announced the issuance of 7,903,778 new ordinary shares following the exercise of options by former employees. These new shares are expected to be admitted to trading on AIM on February 3, 2026. Following this admission, the Company's total number of ordinary shares in issue and total voting rights will be 705,103,778. This figure will serve as the denominator for shareholders calculating their notification obligations under the FCA's Disclosure Guidance and Transparency Rules.
Select text to share a quote on X · sign in to keep highlights & notes in your POLB notes
27 January 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has issued and allotted a total of 7,903,778 new ordinary shares of 0.02 pence each in the capital of the Company ("Ordinary Shares") following the exercise of options by former employees of the Company.
Application has been made to the London Stock Exchange for the 7,903,778 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 February 2026.
Total Voting Rights
After Admission, the total number of Ordinary Shares in issue will be 705,103,778 and the total number of voting rights will therefore be 705,103,778. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.